Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates

2019119 citationsJournal Articlegreen Open Access

Authors

Bram Verstockt · KU Leuven

Erwin Dreesen · KU Leuven

Maja Noman · KU Leuven

An Outtier · KU Leuven

Nathalie Van den Berghe · KU Leuven

Isolde Aerden · KU Leuven

Griet Compernolle · KU Leuven

Abstract

In this cohort of refractory CD patients, ustekinumab showed good clinical remission rates but limited endoscopic remission after 24 weeks. Our data suggest that higher doses may be required to achieve better endoscopic outcomes.

Topics & Keywords

Inflammatory Bowel Disease Eosinophilic Esophagitis Immunodeficiency and Autoimmune Disorders

Publication Details

Published in: Journal of Crohn s and Colitis

Volume 13, Issue 7, pp. 864-872

DOI: 10.1093/ecco-jcc/jjz008

Field-Weighted Citation Impact: 14.14

Command Palette

Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates

Authors

Abstract

Topics & Keywords

Publication Details